Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
By O. Landgren, R. Kyle, Ruth M. Pfeiffer, J. Katzmann, N. Caporaso, R. Hayes, A. Dispenzieri, Shaji K. Kumar, R. Clark, D. Baris and 2 more. Blood, 2009
1,094 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8d08c3026f50dca330d411cb7476cc25f10b2cf7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, result): “tomatic premalignant stage termed monoclonal gammopathy of undetermined significance (MGUS).(10,11) MGUS is present in approximately 5% of the population above the age of 50, and the prevalence is approximately two-fold higher in Blacks compared with Whites.”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Almost all patients with multiple myeloma evolve from an asymptomatic pre-malignant stage termed monoclonal gammopathy of undetermined significance (MGUS).(9,10) It is present in over 3% of the population above the age of 50,(11,12) and the prevalence is approximately 2-fold higher in blacks compare”